ENHANCE trial: is there a role for ezetimibe in managing dyslipidemia?
The results of the ENHANCE (Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression) have been published in the New England Journal of Medicine and have been accompanied by editorials and response from the lay press. Ezetimibe, a drug that inhibits intestinal absorption of cholesterol, is marked alone (Zetia) and in combination with simvastatin, a statin (Vytorin). Annual prescriptions for both medications have steadily increased in the United States since their introduction to market. According to a cohort study conducted by Jackevicius and colleagues, ezetimibe prescriptions have increased by an average of 27,200 per month (2002 to 2006) and ezetimibe/simvastatin prescriptions have increased by an average of 61,000 per month (2004 to 2006) in the United States. Prescriptions for ezetimibe have also increased in Canada (from 2003 to 2006), but not to the degree that they have in the United States (p<0.001). Furthermore, this cohort study reveals that duri
Related Questions
- There are several trial accesses available as on now. Please clarify whether ACM Digital Library & J-Gate will be available on regular basis or only just for few months?
- Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretrovirals or Add Lipid-Lowering Agents?
- ENHANCE trial: is there a role for ezetimibe in managing dyslipidemia?
